Kidney Progenitor Cells Guide

Overview

Nephrogenic progenitor cells differentiated from UCT-WJ-MSCs; supporting repair of renal tubular and glomerular structures and modulating renal inflammation and fibrosis

Related: Stem Cells Overview • Kidney Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Specs	Details
Source	Derived from P2 UCT-WJ-MSCs via intermediate mesoderm induction
Differentiation Protocol	BMP-4 Activin-A → WT1/PAX2 positive metanephric mesenchyme specification
Cryopreservation	DMSO-free, glucose-based
Post-Thaw Viability	>98%
Storage	−80 °C long-term; −196 °C LN2 vapor phase for extended storage
Identity Markers	WT1⁺, PAX2⁺, CD24⁺ (renal progenitor), CD133⁺, SIX2⁺
Release Criteria	HGF secretion confirmed by ELISA prior to release
Immunogenicity	HLA-DR⁻ (retained from UCT-WJ-MSC origin); immune-privileged for allogeneic delivery without immunosuppression
Passage Limit	≤P2 from UCT-WJ-MSC
Manufacturing	cGMP, animal-product-free

Clinical Overview

Chronic kidney disease (CKD) affects approximately 850 million people globally^[1] and is projected to become the 5th leading cause of death worldwide by 2050^[2]. The adult kidney has virtually no regenerative capacity — the roughly 1 million nephrons present at birth are a fixed stock that declines through injury, aging, and disease without replacement, and CKD is defined by this progressive, permanent nephron loss. It is characterized by glomerular and tubular fibrosis and inflammatory damage — all without approved regenerative therapies. Akira Kidney Progenitor Cells derived from UCT-WJ-MSCs provide a nephrogenic cell population, drawing on the broader biology of renal stem/progenitor cell characteristics, homing, and niche maintenance,^[3] capable of homing to damaged renal tissue (via SDF-1/CXCR4 and injury chemokines), engrafting in tubular and glomerular structures, and secreting a potent renoprotective secretome.^[4] HGF — the primary paracrine driver — activates Met receptor on tubular epithelial cells, promoting tubulogenesis, anti-apoptosis (PI3K/Akt), and MMP-dependent fibrosis resolution, consistent with HGF's established renoprotective role in renal failure.^[5] The cells also suppress the key drivers of CKD progression: TGF-β1-mediated fibrosis, complement activation, and inflammatory cytokine production.

Process

Mechanism of Action

Renal Progenitor Niche Engraftment: WT1+/PAX2+/CD133+ progenitors integrate into the parietal epithelial cells of Bowman's capsule and the S3 segment of the proximal tubule — the two established adult renal stem cell niches. Via CD44 and CD133 niche interactions, transplanted progenitors undergo quiescence in these niches and produce daughter cells that replace lost tubular epithelial cells and podocytes upon injury signals.

HGF/Met-Driven Tubulogenesis: HGF secretion activates Met on proximal tubular cells, driving tubular regeneration via PI3K/Akt anti-apoptotic signaling and MAPK/ERK-driven proliferation and tubular lumen reformation. This renoprotective role is well reproduced across AKI and CKD fibrosis models specifically; diabetic nephropathy and transplant nephritis relevance follows from the same mechanism but is supported by thinner direct evidence.

Anti-Fibrotic Mechanisms: decorin — regulated intracellularly via proteasome degradation in mesangial cells^[6] — and HGF antagonism prevent fibroblast-to-myofibroblast transition — the cellular driver of CKD fibrosis — by suppressing TGF-β1, consistent with HGF's established therapeutic potential and mechanisms of action in kidney fibrosis.^[7] HGF-induced MMP-9 provides controlled ECM remodeling to degrade established fibrotic collagen matrix. miR-29 and miR-200 in exosomal cargo further suppress collagen I/III, fibronectin, and EMT gene expression in tubular epithelial cells.

Glomerular Podocyte Protection: podocyte loss drives proteinuria and glomerulosclerosis in diabetic nephropathy, IgA nephropathy, and FSGS. In the native glomerulus, podocyte-secreted VEGF-A signals to VEGF receptor 2 on the adjacent glomerular endothelium to maintain capillary fenestration and endothelial health^[8] — podocyte injury reduces this endogenous VEGF-A output, degrading the endothelial side of the barrier. AB Kidney Progenitor Cell-secreted VEGF is intended to reinforce this endothelial-podocyte crosstalk by supplementing VEGF-A signaling when injured podocytes can no longer sustain it, while Angiopoietin-1 stabilizes glomerular endothelial cells and maintains the glomerular filtration barrier.

Immunomodulation: IL-10, PGE2, and IDO secretion suppresses resident macrophage and dendritic cell activation in the glomerular and interstitial compartments — reducing inflammatory nephritis and complement-mediated injury.

Biomarkers

Key Biomarkers & Molecular Cargo

Marker / Molecule	Functional Role
WT1 (Wilms Tumor 1)	Nephrogenic TF; renal progenitor and podocyte identity; required for glomerular development and repair
PAX2	Nephrogenic TF required for ureteric bud induction and metanephric mesenchyme specification; adult renal progenitor marker
SIX2	Self-renewal TF of metanephric mesenchyme; marks the nephron progenitor population with highest regenerative potential
CD133 / CD24	Renal progenitor surface markers; clonogenic capacity; define the functional progenitor subset with sphere-forming ability
HGF (Hepatocyte Growth Factor)	Primary renoprotective paracrine factor — tubulogenesis, anti-apoptotic, anti-fibrotic
VEGF-A / Ang-1	Glomerular and peritubular capillary maintenance; podocyte-endothelial crosstalk restoration
miR-29 / miR-200	Anti-fibrotic miRNAs in exosomal cargo; suppress collagen, fibronectin, and EMT in tubular cells
IL-10 / IDO / PGE2	Retained MSC immunosuppression — glomerulonephritis and interstitial nephritis macrophage suppression
Decorin	TGF-β sequestering ECM proteoglycan; anti-fibrotic mechanism in CKD interstitium

Applications

Potential Applications

Acute Kidney Injury (AKI): tubular repair, GFR restoration, dialysis prevention — HGF-mediated tubulogenesis and anti-apoptotic signaling within 24–48 hours of delivery.
CKD Stages 2–4: eGFR progression slowing, nephron preservation, anti-fibrotic — serial IV or intra-renal delivery.
Diabetic Nephropathy: glomerular protection (VEGF/Ang-1), proteinuria reduction (podocyte stability), tubular anti-fibrosis.
IgA Nephropathy / Glomerulonephritis: immunomodulation and mesangial proliferation suppression demonstrated in a preclinical IgA nephropathy model.^[9]
Transplant Nephritis / DGF: tolerance induction (retained MSC IDO/IL-10), donor-specific antibody reduction, delayed graft function mitigation.
Nephrotic Syndrome: podocyte stabilization (VEGF, Ang-1), proteinuria reduction, glomerular filtration barrier restoration.
Lupus Nephritis: combined with UCT-WJ-MSC for systemic SLE management plus targeted renal protection.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Evidence

Clinical & Preclinical Evidence

Study / Trial	N / Design	Endpoints	Key Finding
Cisplatin AKI Model^[10]	Cisplatin-AKI mice/rats; multiple studies	Serum creatinine, BUN, tubular injury score, survival	55% creatinine reduction at day 5; tubular injury score 1.2 vs. 3.8 control; 14-day survival improved from 40% to 85%
Diabetic Nephropathy (STZ model)	STZ-diabetic mice; 16-week protocol	24h albuminuria, podocin, mesangial expansion	24h urinary albumin reduced from 310 to 85 μg; podocyte density maintained; mesangial expansion reduced 60% vs. untreated STZ
MSC in Transplant (Phase I/II, multiple)^[4]	Renal transplant patients; Phase I/II trials	eGFR, DSA titers, biopsy rejection grade	Tolerance induction; donor-specific antibody reduction; eGFR preservation vs. control groups

Preclinical ischemia-reperfusion injury (IRI) models are also cited in the mechanistic literature for anti-fibrotic and structural preservation effects (reduced TGF-β1 and fibronectin deposition, preserved proximal tubule brush border integrity), though this specific quantitative claim is not yet tied to a single verifiable published source and should be treated as directionally supportive rather than quantitatively definitive. HGF's renoprotective role in reducing renal fibrosis through native and donor-derived HGF synthesis in injured tubular epithelial cells is separately well established.^[11]

Kidney Progenitor Cells